Fidelity Investments’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Fidelity Investments’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,000	Closed	-$409K	–	5809
2024 Q2	$409K	Buy	+10,000	New	+$416K	﹤0.01%	2801

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Fidelity Investments's CERE Position: Q3 2024 in Review

Fidelity Investments sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 4,880 shares — an estimated $200K sold.

Fidelity Investments first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $777M in Q1 2022. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Fidelity Investments reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Fidelity Investments sold 4,880 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $200K.
Fidelity Investments first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
Fidelity Investments's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $777M in Q1 2022.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Fidelity Investments's 13F filing for Q3 2024, filed 13 Nov 2024.